Jonathan I. Gear

Jonathan I. Gear

Auto-generated profile, based on publicly available information

Jonathan I. Gear

Joint Department of Physics, Royal Marsden NHSFT & Institute of Cancer Research, Sutton, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2018 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
JGJonathan I. Gear
Jonathan I. Gear
MCMaurice G. Cox
Maurice G. Cox
JGJohan Gustafsson
Johan Gustafsson
KGKatarina Sjögreen Gleisner
Katarina Sjögreen Gleisner
IMIain Murray
Iain Murray
GFGlenn D. Flux
Glenn D. Flux
A framework is proposed for modelling the uncertainty in the measurement processes constituting the dosimetry chain that are involved in internal absorbed dose calculations. The starting point is the basic model for absorbed dose in a site of interest as the product of the cumulated activity and a dose factor. In turn, the cumulated activity is given by the area under a time–activity curve derived from a time sequence of activity values. Each activity value is obtained in terms of a count rate, a calibration factor and a recovery coefficient (a correction for partial volume effects). The method to determine the recovery coefficient and the dose factor, both of which are dependent on the size of the volume of interest (VOI), are described. Consideration is given to propagating estimates of the quantities concerned and their associated uncertainties through the dosimetry chain to obtain an estimate of mean absorbed dose in the VOI and its associated uncertainty. This approach is demonstrated in a clinical example.

5 August 2016 in EJNMMI Physics
Verified
Journal Article
Open access
PDF file
JGJonathan I. Gear
Jonathan I. Gear
CCCraig Cummings
Craig Cummings
ACAllison J. Craig
Allison J. Craig
ADAntigoni Divoli
Antigoni Divoli
CLClive D. C. Long
Clive D. C. Long
GFGlenn D. Flux
Glenn D. Flux
The use of selective internal radiation therapy (SIRT) is rapidly increasing, and the need for quantification and dosimetry is becoming more widespread to facilitate treatment planning and verification. The aim of this project was to develop an anthropomorphic phantom that can be used as a validation tool for post-SIRT imaging and its application to dosimetry. The phantom design was based on anatomical data obtained from a T1-weighted volume-interpolated breath-hold examination (VIBE) on a Siemens Aera 1.5 T MRI scanner. The liver, lungs and abdominal trunk were segmented using the Hermes image processing workstation. Organ volumes were then uploaded to the Delft Visualization and Image processing Development Environment for smoothing and surface rendering. Triangular meshes defining the iso-surfaces were saved as stereo lithography (STL) files and imported into the Autodesk® Meshmixer software. Organ volumes were subtracted from the abdomen and a removable base designed to allow access to the liver cavity. Connection points for placing lesion inserts and filling holes were also included. The phantom was manufactured using a Stratasys Connex3 PolyJet 3D printer. The printer uses stereolithography technology combined with ink jet printing. Print material is a solid acrylic plastic, with similar properties to polymethylmethacrylate (PMMA). Measured Hounsfield units and calculated attenuation coefficients of the material were shown to also be similar to PMMA. Total print time for the phantom was approximately 5 days. Initial scans of the phantom have been performed with Y-90 bremsstrahlung SPECT/CT, Y-90 PET/CT and Tc-99m SPECT/CT. The CT component of these images compared well with the original anatomical reference, and measurements of volume agreed to within 9 %. Quantitative analysis of the phantom was performed using all three imaging techniques. Lesion and normal liver absorbed doses were calculated from the quantitative images in three dimensions using the local deposition method. 3D printing is a flexible and cost-efficient technology for manufacture of anthropomorphic phantom. Application of such phantoms will enable quantitative imaging and dosimetry methodologies to be evaluated, which with optimisation could help improve outcome for patients.

6 March 2020 in EJNMMI Physics
Verified
Journal Article
Open access
PDF file
ICIn collaboration with the EANM Dosimetry Committee
In collaboration with the EANM Dosimetry Committee
JGJonathan Gear
Jonathan Gear
CCCarlo Chiesa
Carlo Chiesa
MLMichael Lassmann
Michael Lassmann
PGPablo Mínguez Gabiña
Pablo Mínguez Gabiña
GFGlenn Flux
Glenn Flux
The purpose of the EANM Dosimetry Committee Series on “Standard Operational Procedures for Dosimetry” (SOP) is to provide advice to scientists and clinicians on how to perform patient-specific absorbed dose assessments. This SOP describes image and data acquisition parameters and dosimetry calculations to determine the absorbed doses delivered to whole-body, tumour and normal organs following a therapeutic administration of131I mIBG for the treatment of neuroblastoma or adult neuroendocrine tumours. Recommendations are based on evidence in recent literature where available and on expert opinion within the community. This SOP is intended to promote standardisation of practice within the community and as such is based on the facilities and expertise that should be available to any centre able to perform specialised treatments with radiopharmaceuticals and patient-specific dosimetry. A clinical example is given to demonstrate the application of the absorbed dose calculations.

7 January 2019 in EJNMMI Physics
Verified
Journal Article
Open access
PDF file
JGJonathan I. Gear
Jonathan I. Gear
JTJan Taprogge
Jan Taprogge
OWOwen White
Owen White
GFGlenn D. Flux
Glenn D. Flux
The aim of this work was to characterise the attenuation properties of 3D-printed tungsten and to assess the feasibility for its use in gamma camera collimator manufacture. 3D-printed tungsten disks were produced using selective laser melting (SLM). Measurements of attenuation were made through increasing numbers of disks for a Tc-99m (140 keV) and I-131 (364 keV) source. The technique was validated by repeating the measurements with lead samples. Resolution measurements were also made with a SLM tungsten collimator and compared to Monte Carlo simulations of the experimental setup. Different collimator parameters were simulated and compared against the physical measurements to investigate the effect on image quality. The measured disk thicknesses were on average 20% above the specified disk thicknesses. The measured attenuation for the tungsten samples were lower than the theoretical value determined from the National Institute of Standards and Technology (NIST) cross-sectional database (Berger and Hubbell, XCOM: photon cross-sections on a personal computer, 1987). The laser scan strategy had a significant influence on material attenuation (up to 40% difference). Results of these attenuation measurements indicate that the density of the SLM material is lower than the raw tungsten density. However, an improved performance compared to a lead collimator was observed. The SLM tungsten collimator was adequately simulated as 80% density and 110% septal thickness. Scatter and septal penetration were 17% less than a similar lead collimator and 33% greater than tungsten at 100% density. SLM manufacture of tungsten collimators is feasible. Attenuation properties of SLM tungsten are superior to the lead alternative and the opportunity for bespoke collimator design is appealing.

16 December 2021 in Thyroid®
Verified
Journal Article
Open access
JTJan Taprogge
Jan Taprogge
PGPaul Gape
Paul Gape
LCLily Carnegie-Peake
Lily Carnegie-Peake
IMIain Murray
Iain Murray
JGJonathan I. Gear
Jonathan I. Gear
GFGlenn D. Flux
Glenn D. Flux
Background: Patients with Graves' disease are commonly treated with radioiodine. There remains controversy over whether the aim of treatment should be to achieve euthyroidism or hypothyroidism, and whether treatments should be administered with standard levels of radioactivity or personalized according to the radiation absorbed doses delivered to the thyroid. The aim of this review was to investigate whether a relationship exists between radiation absorbed dose and treatment outcome. Methods: A systematic review and meta-analysis of all reports published before February 13, 2020, were performed using PubMed, Web of Science, OVID MEDLINE, and Embase. Proportion of patients achieving nonhyperthyroid status was the primary outcome. Secondary outcomes were proportion of patients who were specifically euthyroid or hypothyroid. A random-effects meta-analysis of proportions was performed for primary and secondary outcomes, and the impact of the radiation absorbed dose on treatment outcome was assessed through meta-regression. The study is registered with PROSPERO (CRD42020175010). Results: A total of 1122 studies were identified of which 15, comprising 2303 Graves' disease patients, were eligible for the meta-analysis. A strong association was found between radiation absorbed dose and nonhyperthyroid and hypothyroid outcomes (odds ratio [OR] = 1.11 [95% confidence interval {CI} 1.08–1.14] and OR = 1.09 [CI 1.06–1.12] per 10 Gy increase). Higher rates of euthyroid outcome were found for radiation absorbed doses within the range 120–180 Gy when compared with outside this range ( n = 1172, OR = 2.50 [CI 1.17–5.35], p = 0.018). A maximum euthyroid response of 38% was identified at a radiation absorbed dose of 128 Gy. Conclusions: The presented radiation absorbed dose–response relationships can facilitate personalized treatment planning for radioiodine treatment of patients with Graves' disease. Further studies are required to determine how patient-specific covariates can inform personalized treatments.

22 April 2023 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
JGJonathan Gear
Jonathan Gear
CSCaroline Stokke
Caroline Stokke
CTChristelle Terwinghe
Christelle Terwinghe
SGSilvano Gnesin
Silvano Gnesin
MSMattias Sandström
Mattias Sandström
PGPablo Minguez Gabiña
Pablo Minguez Gabiña
Dosimetry can be a useful tool for personalization of molecular radiotherapy (MRT) procedures, enabling the continuous development of theranostic concepts. However, the additional resource requirements are often seen as a barrier to implementation. This guide discusses the requirements for dosimetry and demonstrates how a dosimetry regimen can be tailored to the available facilities of a centre. The aim is to help centres wishing to initiate a dosimetry service but may not have the experience or resources of some of the more established therapy and dosimetry centres. The multidisciplinary approach and different personnel requirements are discussed and key equipment reviewed example protocols demonstrating these factors are given in the supplementary material for the main therapies carried out in nuclear medicine, including [131I]-NaI for benign thyroid disorders, [177Lu]-DOTATATE and131I-mIBG for neuroendocrine tumours and [90Y]-microspheres for unresectable hepatic carcinoma.